Transgenic inhibition of glial NF-kappa B reduces pain behavior and inflammation after peripheral nerve injury

Eugene Fu, Yan Ping Zhang, Jacqueline Sagen, Keith A Candiotti, Paul D. Morton, Daniel J Liebl, John R. Bethea, Roberta Brambilla

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

The transcription factor nuclear factor kappa B (NF-κB) is a key regulator of inflammatory processes in reactive glial cells. We utilized a transgenic mouse model (GFAP-IκBα-dn) where the classical NF-κB pathway is inactivated by overexpression of a dominant negative (dn) form of the inhibitor of kappa B (IκBα) in glial fibrillary acidic protein (GFAP)-expressing cells, which include astrocytes, Schwann cells, and satellite cells of the dorsal root ganglion (DRG) and sought to determine whether glial NF-κB inhibition leads to a reduction in pain behavior and inflammation following chronic constriction injury (CCI) of the sciatic nerve. As expected, following CCI nuclear translocation, and hence activation, of NF-κB was detected only in the sciatic nerve of wild type (WT) mice, and not in GFAP-IκBα-dn mice, while upregulation of GFAP was observed in the sciatic nerve and DRGs of both WT and GFAP-IκBα-dn mice, indicative of glial activation. Following CCI, mechanical and thermal hyperalgesia were reduced in GFAP-IκBα-dn mice compared to those in WT, as well as gene and protein expression of CCL2, CCR2 and CXCL10 in the sciatic nerve. Additionally, gene expression of TNF, CCL2, and CCR2 was reduced in the DRGs of transgenic mice compared to those of WT after CCI. We can therefore conclude that transgenic inhibition of NF-κB in GFAP-expressing glial cells attenuated pain and inflammation after peripheral nerve injury. These findings suggest that targeting the inflammatory response in Schwann cells and satellite cells may be important in treating neuropathic pain.

Original languageEnglish
Pages (from-to)509-518
Number of pages10
JournalPain
Volume148
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Peripheral Nerve Injuries
NF-kappa B
Glial Fibrillary Acidic Protein
Neuroglia
Inflammation
Pain
Sciatic Nerve
Constriction
Diagnosis-Related Groups
Schwann Cells
Hyperalgesia
Wounds and Injuries
Transgenic Mice
Gene Expression
Spinal Ganglia
Neuralgia
Inhibition (Psychology)
Astrocytes
Transcription Factors
Up-Regulation

Keywords

  • Chronic constriction injury
  • NF-kappa B
  • Pain
  • Peripheral glia

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

Transgenic inhibition of glial NF-kappa B reduces pain behavior and inflammation after peripheral nerve injury. / Fu, Eugene; Zhang, Yan Ping; Sagen, Jacqueline; Candiotti, Keith A; Morton, Paul D.; Liebl, Daniel J; Bethea, John R.; Brambilla, Roberta.

In: Pain, Vol. 148, No. 3, 01.03.2010, p. 509-518.

Research output: Contribution to journalArticle

@article{964fabe0884049028451f2a0849c6e68,
title = "Transgenic inhibition of glial NF-kappa B reduces pain behavior and inflammation after peripheral nerve injury",
abstract = "The transcription factor nuclear factor kappa B (NF-κB) is a key regulator of inflammatory processes in reactive glial cells. We utilized a transgenic mouse model (GFAP-IκBα-dn) where the classical NF-κB pathway is inactivated by overexpression of a dominant negative (dn) form of the inhibitor of kappa B (IκBα) in glial fibrillary acidic protein (GFAP)-expressing cells, which include astrocytes, Schwann cells, and satellite cells of the dorsal root ganglion (DRG) and sought to determine whether glial NF-κB inhibition leads to a reduction in pain behavior and inflammation following chronic constriction injury (CCI) of the sciatic nerve. As expected, following CCI nuclear translocation, and hence activation, of NF-κB was detected only in the sciatic nerve of wild type (WT) mice, and not in GFAP-IκBα-dn mice, while upregulation of GFAP was observed in the sciatic nerve and DRGs of both WT and GFAP-IκBα-dn mice, indicative of glial activation. Following CCI, mechanical and thermal hyperalgesia were reduced in GFAP-IκBα-dn mice compared to those in WT, as well as gene and protein expression of CCL2, CCR2 and CXCL10 in the sciatic nerve. Additionally, gene expression of TNF, CCL2, and CCR2 was reduced in the DRGs of transgenic mice compared to those of WT after CCI. We can therefore conclude that transgenic inhibition of NF-κB in GFAP-expressing glial cells attenuated pain and inflammation after peripheral nerve injury. These findings suggest that targeting the inflammatory response in Schwann cells and satellite cells may be important in treating neuropathic pain.",
keywords = "Chronic constriction injury, NF-kappa B, Pain, Peripheral glia",
author = "Eugene Fu and Zhang, {Yan Ping} and Jacqueline Sagen and Candiotti, {Keith A} and Morton, {Paul D.} and Liebl, {Daniel J} and Bethea, {John R.} and Roberta Brambilla",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.pain.2010.01.001",
language = "English",
volume = "148",
pages = "509--518",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Transgenic inhibition of glial NF-kappa B reduces pain behavior and inflammation after peripheral nerve injury

AU - Fu, Eugene

AU - Zhang, Yan Ping

AU - Sagen, Jacqueline

AU - Candiotti, Keith A

AU - Morton, Paul D.

AU - Liebl, Daniel J

AU - Bethea, John R.

AU - Brambilla, Roberta

PY - 2010/3/1

Y1 - 2010/3/1

N2 - The transcription factor nuclear factor kappa B (NF-κB) is a key regulator of inflammatory processes in reactive glial cells. We utilized a transgenic mouse model (GFAP-IκBα-dn) where the classical NF-κB pathway is inactivated by overexpression of a dominant negative (dn) form of the inhibitor of kappa B (IκBα) in glial fibrillary acidic protein (GFAP)-expressing cells, which include astrocytes, Schwann cells, and satellite cells of the dorsal root ganglion (DRG) and sought to determine whether glial NF-κB inhibition leads to a reduction in pain behavior and inflammation following chronic constriction injury (CCI) of the sciatic nerve. As expected, following CCI nuclear translocation, and hence activation, of NF-κB was detected only in the sciatic nerve of wild type (WT) mice, and not in GFAP-IκBα-dn mice, while upregulation of GFAP was observed in the sciatic nerve and DRGs of both WT and GFAP-IκBα-dn mice, indicative of glial activation. Following CCI, mechanical and thermal hyperalgesia were reduced in GFAP-IκBα-dn mice compared to those in WT, as well as gene and protein expression of CCL2, CCR2 and CXCL10 in the sciatic nerve. Additionally, gene expression of TNF, CCL2, and CCR2 was reduced in the DRGs of transgenic mice compared to those of WT after CCI. We can therefore conclude that transgenic inhibition of NF-κB in GFAP-expressing glial cells attenuated pain and inflammation after peripheral nerve injury. These findings suggest that targeting the inflammatory response in Schwann cells and satellite cells may be important in treating neuropathic pain.

AB - The transcription factor nuclear factor kappa B (NF-κB) is a key regulator of inflammatory processes in reactive glial cells. We utilized a transgenic mouse model (GFAP-IκBα-dn) where the classical NF-κB pathway is inactivated by overexpression of a dominant negative (dn) form of the inhibitor of kappa B (IκBα) in glial fibrillary acidic protein (GFAP)-expressing cells, which include astrocytes, Schwann cells, and satellite cells of the dorsal root ganglion (DRG) and sought to determine whether glial NF-κB inhibition leads to a reduction in pain behavior and inflammation following chronic constriction injury (CCI) of the sciatic nerve. As expected, following CCI nuclear translocation, and hence activation, of NF-κB was detected only in the sciatic nerve of wild type (WT) mice, and not in GFAP-IκBα-dn mice, while upregulation of GFAP was observed in the sciatic nerve and DRGs of both WT and GFAP-IκBα-dn mice, indicative of glial activation. Following CCI, mechanical and thermal hyperalgesia were reduced in GFAP-IκBα-dn mice compared to those in WT, as well as gene and protein expression of CCL2, CCR2 and CXCL10 in the sciatic nerve. Additionally, gene expression of TNF, CCL2, and CCR2 was reduced in the DRGs of transgenic mice compared to those of WT after CCI. We can therefore conclude that transgenic inhibition of NF-κB in GFAP-expressing glial cells attenuated pain and inflammation after peripheral nerve injury. These findings suggest that targeting the inflammatory response in Schwann cells and satellite cells may be important in treating neuropathic pain.

KW - Chronic constriction injury

KW - NF-kappa B

KW - Pain

KW - Peripheral glia

UR - http://www.scopus.com/inward/record.url?scp=76349109675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349109675&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2010.01.001

DO - 10.1016/j.pain.2010.01.001

M3 - Article

C2 - 20097004

AN - SCOPUS:76349109675

VL - 148

SP - 509

EP - 518

JO - Pain

JF - Pain

SN - 0304-3959

IS - 3

ER -